Anti-emap ii antibody and use thereof

Abstract

The present invention relates to an anti-EMAP II antibody or an antigen-binding fragment thereof, a nucleic acid molecule for coding the same, or a preparation method thereof. Also, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in preventing, treating or diagnosing EMAP II-mediated diseases, for example, TNF-α-mediated disease or Alzheimer's disease. Furthermore, the present invention provides a method for using the anti-EMAP II antibody or the antigen-binding fragment thereof in detecting or quantifying an EMAP II antigen. The antibody of the present invention may exhibit a more improved antigen-binding capacity compared to existing anti-EMAP antibodies and may treat the TNF-α-mediated disease more effectively.

1 .- 16 . (canceled) 
     
     
         17 . A method for treating neuroinflammatory disease or Alzheimer's disease, including administering a therapeutically effective amount of a composition comprising an anti-EMAP II antibody or the antigen-binding fragment thereof, wherein the anti-EMAP II antibody or the antigen-binding fragment thereof, comprising a light chain variable region, containing a light chain CDR1 consisting of SEQ ID NO: 7, a light chain CDR2 consisting of SEQ ID NO: 9, and a light chain CDR3 consisting of SEQ ID NO: 11; and a heavy chain variable region, containing a heavy chain CDR1 consisting of SEQ ID NO: 12, a heavy chain CDR2 consisting of SEQ ID NO: 14, and a heavy chain CDR3 consisting of SEQ ID NO: 16. 
     
     
         18 . The method according to  claim 17 , wherein the antibody comprises a light chain variable region consisting of SEQ ID NO: 3; and a heavy chain variable region consisting of SEQ ID NO: 4. 
     
     
         19 . The method according to  claim 17 , characterized in that the antibody is a humanized antibody. 
     
     
         20 . The method according to  claim 17 , wherein the antibody comprises a kappa or human IgG-derived constant region. 
     
     
         21 . The method according to  claim 17 , characterized in that the antigen binding fragment is Fab, F(ab′), F(ab′)2 or Fv.